Meena Okera

Meena Okera

Auto-generated profile, based on publicly available information

Meena Okera

Adelaide Cancer Centre

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CRChristina H. Ruhlmann
Christina H. Ruhlmann
TITrine Zeeberg Iversen
Trine Zeeberg Iversen
MOMeena Okera
Meena Okera
AMAida Muhic
Aida Muhic
GKGunnar Balle Kristensen
Gunnar Balle Kristensen
Jørn HerrstedtJørn Herrstedt
Jørn Herrstedt

1 July 2014 in Case Reports in Oncological Medicine
Verified
Journal Article
Open access
PDF file
SFStephanie Du Four
Stephanie Du Four
AHAngela Hong
Angela Hong
MCMatthew Chan
Matthew Chan
MCMichail Charakidis
Michail Charakidis
JDJohnny Duerinck
Johnny Duerinck
BNBart Neyns
Bart Neyns
Four cases previously treated with ipilimumab with a total of six histologically confirmed symptomatic lesions of RNB without any sign of active tumour following stereotactic irradiation of MBM are reported. These lesions were all originally thought to be disease recurrence. In two cases, ipilimumab was given prior to SRT; in the other two ipilimumab was given after SRT. The average time from first ipilimumab to RNB was 15 months. The average time from SRT to RNB was 11 months. The average time from first diagnosis of MBM to last follow-up was 20 months at which time three patients were still alive, one with no evidence of disease. These cases represent approximately three percent of the total cases of melanoma and ten percent of those cases treated with ipilimumab irradiated in our respective centres collectively. We report this to highlight this new problem so that others may have a high index of suspicion, allowing, if clinically warranted, aggressive surgical salvage, possibly resulting in increased survival. Further studies prospectively collecting data to understand the denominator of this problem are needed to determine whether this problem is just the result of longer survival or whether there is some synergy between these two modalities that are increasingly being used together.

1 June 2021
Verified
Conference Paper
Closed access
EGEm Grischke
Em Grischke
Patrick NevenPatrick Neven
Patrick Neven
SJS Johnston
S Johnston
MTMasakazu Toi
Masakazu Toi
Joohyuk SohnJoohyuk Sohn
Joohyuk Sohn
SSSledge Sledge
Sledge Sledge
Goal In MONARCH 2 (M2), abemaciclib+fulvestrant demonstrated statistically significant improvements in PFS and OS versus placebo+fulvestrant in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC. Numerically more pronounced PFS and OS improvement was noted in subgroups with visceral disease and primary endocrine resistance. We report efficacy data for M2 with respect to 1L and 2L subgroups (last line of endocrine therapy [ET] in (neo)adjuvant and metastatic setting, respectively). Material/method In M2 (global, randomised, double-blind Phase3 trial of abemaciclib+fulvestrant [n = 446]/placebo+fulvestrant [n = 223]), women with ET-resistant (ETR), HR+, HER2- ABC regardless of menopausal status were stratified by site of metastasis (visceral, bone-only, other) and resistance to prior ET (primary versus secondary). Exploratory subgroup analyses of PFS and OS were conducted in ITT patients with 1L versus 2L. Hazard ratios (HR) were estimated using Cox models. Results At data cut-off (June-20-2019), effect of abemaciclib+fulvestrant versus placebo+fulvestrant was consistent across 1L (n = 265/133) and 2L (n = 170/86) subgroups (no statistically significant interaction for PFS[p=0.341] or OS[p=0.265]). For 1L patients, PFS(HR=0.57; 95 %CI=0.45,0.73) and OS(HR=0.85; 95 %CI=0.64, 1.14) improved. Similar efficacy results were observed for 2L patients (PFS: HR=0.48[95 %CI=0.36,0.64]; OS: HR=0.66[95 %CI=0.46,0.94]). Numerically largest effects in 1L population were noted in patients with less favourable prognostic factors like primary ETR (PFS: HR=0.40[95 %CI=0.26,0.63]; OS: HR=0.58[95 %CI=0.35, 0.97]) and visceral disease (PFS: HR=0.54[95 % CI=0.39,0.73]; OS: HR=0.82[95 %CI=0.57, 1.17]). Summary Statistically significant benefit observed in M2 was consistent across 1L and 2L patients. In 1L patients (abemaciclib+fulvestrant), PFS and OS improved (most pronounced effects noted in patients with less favourable prognostic factors). Publication Date: 01 June 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany